Physician profile
Avais Masud
NPI 1114983541
$7,130.42
in general payments reported to CMS, 2019-2025
13 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $105 · 2021: $123 · 2022: $14.34 · 2023: $2,250 · 2024: $4,201 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,900 · Honoraria: $900 · Food and Beverage: $761 · Education: $43.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,900.00 |
| Honoraria | $900.00 |
| Food and Beverage | $760.80 |
| Education | $43.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,335.23 | 2019-2024 | Farxiga |
| Daxor Corporation | $900.00 | 2024 | Bva-100 |
| Vifor Pharma, INC. | $206.51 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $150.00 | 2024 | Terlivaz |
| W. L. Gore & Associates, INC. | $142.73 | 2019 | |
| Opko Pharmaceuticals, LLC | $138.05 | 2024-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $111.30 | 2021-2023 | Jynarque |
| Aurinia Pharma U.S., INC. | $43.00 | 2024 | Lupkynis |
| Amgen INC. | $34.75 | 2025 | Tavneos |
| Nxstage Medical, INC. | $27.72 | 2021 | |
| Calliditas Therapeutics US INC. | $15.40 | 2023 | Tarpeyo |
| Chiesi USA, INC. | $13.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avais Masud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.